Home > Riviste > Giornale Italiano di Dermatologia e Venereologia > Fascicoli precedenti > Giornale Italiano di Dermatologia e Venereologia 2018 December;153(6) > Giornale Italiano di Dermatologia e Venereologia 2018 December;153(6):860-5

ULTIMO FASCICOLO
 

JOURNAL TOOLS

eTOC
Per abbonarsi
Sottometti un articolo
Segnala alla tua biblioteca
 

ARTICLE TOOLS

Publication history
Estratti
Permessi
Per citare questo articolo

 

ORIGINAL ARTICLE   

Giornale Italiano di Dermatologia e Venereologia 2018 December;153(6):860-5

DOI: 10.23736/S0392-0488.18.06064-9

Copyright © 2018 EDIZIONI MINERVA MEDICA

lingua: Inglese

Treatment of facial actinic keratoses with a cream containing octatrienoic acid: a multicenter clinical experience

Mara LOMBARDI 1, Alfredo ROSSI 2, Maria C. FORTUNA 2, Valentina GARELLI 2, Elisa SAMA 3, Daniela SENIS 4, Claudia COSTA 5

1 Department of Dermatology, University of Modena and Reggio Emilia, Modena, Italy; 2 Department of Internal Medicine and Medical Specialties, Sapienza University, Rome, Italy; 3 Department of Dermatology, M. Bufalini Hospital, Cesena, Forlì-Cesena, Italy; 4 Department of Dermatology, Businco Hospital, Cagliari, Italy; 5 Unit of Dermatology, Department of Clinical Medicine and Surgery, University of Naples Federico II, Naples, Italy



BACKGROUND: Actinic keratosis (AKs) are premalignant skin lesions characterized by high rate of transformation in squamous cell carcinoma if not treated. Preclinical published data on parrodiene-derivative 2,4,6-octatrienoic acid, encourages us to study and to evaluate the effect of a topical product containing it in patients affected by mild to moderate actinic keratosis.
METHODS: Seventy subjects with at least 1-3 clinically diagnosed actinic keratosis lesions, non-hyperkeratotic, non-hypertrophic, localized on the face (I-II degree actinic keratosis) were enrolled in the study. The product was applied twice/day for 60 consecutive days.
RESULTS: After 60 days of treatment, a significant improvement in lesions occurred as shown by the decrease in the AKESA Score (P<0.05). Moreover, octatrienoic acid containing cream induced a 90% response rate (63/70 patients P<0.5; 95% confidence interval) with 20% complete remission (14/70 patients, P<0.05). Compared to baseline, a significant number of patients reported improvement of each AKESA sub-score after 60 days of treatment: skin thickness improved in 46 patients (P<0.0001), erythema in 21 patients (P<0.0001) and atrophy in 57 patients (P<0.0348). The average pigmentation score significantly decreased from 1.50 to 0.79 (P<0.05).
CONCLUSIONS: The results of the study, confirmed also by self-assessment, allow us not only to state that the use of topical octatrienoic acid was effective and well tolerated for topical treatment of AKs leading to overall clinical improvement in approximately 90% of subjects treated for 60 days.


KEY WORDS: Keratosis, actinic - Octa-2,4,6-trienoic acid - Administration, topical

inizio pagina